Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Cycle-length evidence

Selank + Semax Blend cycle length: what human studies ran

Not approved — research use only
Short answer: there is no established Selank + Semax Blend cycle length, and we found no human studies that report one.

Treatment and follow-up in human studies

No human study durations are recorded.

What has not been tested

  • On-and-off schedules or breaks between courses.
  • Repeated courses and long-term exposure beyond the periods listed.
  • Selank + Semax Blend combined with other compounds, unless a study above says so.

Frequently asked questions

Is there an established Selank + Semax Blend cycle length?
No. We found no human studies that report a treatment duration for Selank + Semax Blend.
What is the longest human study of Selank + Semax Blend?
None is recorded.
Do study durations tell me how long to use something?
No. A study duration is how long investigators administered a compound to selected participants under monitoring. It is not a recommended course, and a break between courses has not been tested for any compound on this site that is not approved.
Selank + Semax Blend dosing reference Full research page

References

  1. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity Protein Pept Lett. 2018
  2. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission Front Pharmacol. 2016
  3. Semax, an analogue of adrenocorticotropin (4-10), binds specifically and increases levels of brain-derived neurotrophic factor protein in rat basal forebrain J Neurochem. 2006
  4. The occurrence of putative cognitive enhancing research peptides in seized pharmaceutical preparations: An incentive for controlling agencies to prepare for future encounters of the kind Drug Test Anal. 2020
  5. Natural and hybrid ("chimeric") stable regulatory glyproline peptides Pathophysiology. 2005
  6. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions J Am Acad Orthop Surg Glob Res Rev. 2026
  7. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (updated May 14, 2026) FDA. 2026
  8. PubMed search: Selank AND Semax (14 records, none an experiment on the combination; searched 22 October 2026) PubMed. 2026
  9. World Anti-Doping Code International Standard: Prohibited List 2026 WADA. 2026